Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
The company will acquire ImCheck for €350m.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
